This is one of two pathways that deal with DNA damage. It has two central gene products (ATM and TP53) which are connected with the [[Pathway:WP707|other DNA damage response pathway]].
In this pathway there is only one source of DNA damage induction, since most DNA damage induction sources and their involvement are mentioned in the [[Pathway:WP707|first DNA damage response pathway]].
If it is not mentioned differently, the processes take place in the cell cytoplasm.
The purpose of this pathway is to report more gene products and cell condition changes through the DNA damage response pathway and at the same time keep them clearly arranged.
Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP710 CPTAC Assay Portal]
MOUSE:KG38 MOUSE
e6f
e6f
e6f
e6f
e6f
e6f
e6f
e6f
e6f
e6f
e6f
e6f
d17
18004398
PubMed
CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
Nat Rev Cancer
2007
Antoni L
Sodha N
Collins I
Garrett MD
17568790
PubMed
CDC25 phosphatases in cancer cells: key players? Good targets?
Nat Rev Cancer
2007
Boutros R
Lobjois V
Ducommun B
17060944
PubMed
Polycomb silencers control cell fate, development and cancer.
Nat Rev Cancer
2006
Sparmann A
van Lohuizen M
15668327
PubMed
Chromosomal instability in oral cancer cells.
J Dent Res
2005
Reshmi SC
Gollin SM
17768402
PubMed
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
Nat Rev Genet
2007
Wang W
20610534
PubMed
Beta-catenin (CTNNB1) promotes preovulatory follicular development but represses LH-mediated ovulation and luteinization.
Mol Endocrinol
2010
Fan HY
O'Connor A
Shitanaka M
Shimada M
Liu Z
Richards JS
16805667
PubMed
Surviving the breakup: the DNA damage checkpoint.
Annu Rev Genet
2006
Harrison JC
Haber JE
15339658
PubMed
Wagging the dogma; tissue-specific cell cycle control in the mouse embryo.
Cell
2004
Pagano M
Jackson PK
19111245
PubMed
Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?
Lancet Oncol
2009
Chargari C
Toillon RA
Macdermed D
Castadot P
Magnأ¯آ؟آ½أ¯آ؟آ½أژآ© N
15545627
PubMed
Living with or without cyclins and cyclin-dependent kinases.
Genes Dev
2004
Sherr CJ
Roberts JM
17380161
PubMed
p53 in health and disease.
Nat Rev Mol Cell Biol
2007
Vousden KH
Lane DP
14993903
PubMed
Targeting the checkpoint kinases: chemosensitization versus chemoprotection.
Nat Rev Cancer
2004
Zhou BB
Bartek J
16921403
PubMed
Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.
Nat Rev Mol Cell Biol
2006
Gil J
Peters G
17943134
PubMed
The impact of a negligent G2/M checkpoint on genomic instability and cancer induction.
Nat Rev Cancer
2007
Lأ¯آ؟آ½أ¯آ؟آ½أژآ©brich M
Jeggo PA
p53-dependent G1/S DNA damage checkpoint pathway
PW:0000303
Pathway Ontology
15343279
PubMed
Transcription - guarding the genome by sensing DNA damage.
Nat Rev Cancer
2004
Ljungman M
Lane DP
p53 signaling pathway
PW:0000718
Pathway Ontology
15719025
PubMed
The role of BH3-only proteins in the immune system.
Nat Rev Immunol
2005
Strasser A
15688066
PubMed
p53: traffic cop at the crossroads of DNA repair and recombination.
Nat Rev Mol Cell Biol
2005
Sengupta S
Harris CC
14634621
PubMed
The Bcl-2 family: roles in cell survival and oncogenesis.
Oncogene
2003
Cory S
Huang DC
Adams JM